Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Rigel Awarded $16.5 Million from U.S. Department of Defense for Phase 3 Clinical Trial of Fostamatinib in COVID-19 Patients

prnewswireFebruary 01, 2021

Tag: Rigel , fostamatinib , COVID-19 , Tavalisse , DoD

PharmaSources Customer Service